Nimbus
YC W21Seattle, US · Founded 2020 · 3 employees · Inactive · 1 known investors
Nimbus provides automated cost optimization for Datadog customers, reducing their observability expenses without requiring manual intervention from engineering teams.
AI & Machine LearningData & InfrastructureEnterprise SoftwareArtificial IntelligenceInfrastructureOperationsin /nimbushq/@kevins8ycombinator.com ↗
Founders & leadership· Y Combinator alumni (W21)
Investors · 1
Competitors · 6
by search overlapDatadog11 shared keywordsDatadog is a cloud-based monitoring and security platform that provides observability, analytics, and protection for infrastructure, applications, and data across enterprises. The platform serves development, security, and operations teams managing cloud-native and hybrid environments.
Webeyez7 shared keywords
StatusGator5 shared keywords
Qiita4 shared keywordsQiita is a knowledge-sharing platform where engineers post, share, and edit technical articles, and follow users and tags. It serves software engineers and developers, primarily in Japan, as a community content and knowledge-sharing service.
Nullstone4 shared keywordsNullstone provides a developer-focused platform for self-service cloud infrastructure management across multiple providers, eliminating the need for DevOps expertise. The platform automates deployment, environment configuration, and observability for container, serverless, and static applications.
website link3 shared keywords
Companies competing with Nimbus for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
- Earnings call transcript: Nimbus Group posts stronger margins in Q2 2026 By Investing.cominvesting.com · 2026
- Nimbus Therapeutics raises $210 million in one of the larger fundraising rounds this yearstatnews.com · 2023
- Nimbus tacks on $210M in funding as investors swat away IRA concerns | Fierce Biotechfiercebiotech.com · 2023
- Nimbus raises $125M to advance rival to Bristol Myers’ new psoriasis drug | BioPharma Divebiopharmadive.com · 2022
- Nimbus raises $105M for multifront TYK2 clinical trial program | Fierce Biotechfiercebiotech.com · 2021
